Literature DB >> 21572623

A Rare Case of Prosthetic Valve Endocarditis Caused by Extended-spectrum β-Lactamase Producing Escherichia coli.

Harshit H Modi1, Snesha H Modi, Bazgha Rehan Siddiqui, John M Andreoni.   

Abstract

Entities:  

Year:  2011        PMID: 21572623      PMCID: PMC3068594          DOI: 10.4103/0974-777X.77310

Source DB:  PubMed          Journal:  J Glob Infect Dis        ISSN: 0974-777X


× No keyword cloud information.
Sir, Prosthetic heart valve endocarditis accounts for 20% of cases of infective endocarditis.[1] Endocarditis due to non HACEK (Hemophilus species, Actinobacillus actinomycetemcomitan, Cardiobacterium hominis, Eikenella corrodens, Kingella species) Gram negative bacteria is uncommon. Among the Gram negative bacteria, extended-spectrum β –lactamase (ESBL) - producing Escherichia species causing prosthetic valve endocarditis (PVE) is extremely uncommon. Our patient was a 62-years-old African American female with history of mitral regurgitation s/p bioprosthetic mitral valve replacement four years ago, left sided hemiplegia after right basal ganglia infarct and severe penicillin allergy presented to hospital for respiratory distress. Patient was tachypneic, tachycardic, normotensive and febrile with temperature of 39.6ºC. On examination, there was newly found pansystolic murmur grade 2/6 at apex of the heart, diffuse expiratory rales and left sided hemiplegia. There were no peripheral stigmata of endocarditis. Her leukocytes count was 13,000/mm 3with 81% neutrophils, 14% lymphocytes and 5% monocytes. Urinalysis was negative for leukocyte esterase, 1-5 leucocytes/high power field and no bacteria. Roentogenogram showed mild pulmonary congestion. Initial arterial blood gas analysis depicted respiratory acidosis. CT scan of head without contrast showed chronic infarct in right basal ganglia. Patient was admitted to intensive care unit (ICU), supported with non invasive ventilation and treated with intravenous vancomycin and aztreonam for health care associated pneumonia. The Gram-stained smear showed Gram-negative bacilli. On day three, transesophageal echocardiogram (TEE) revealed 5-mm mobile echogenic structure on bioprosthetic mitral valve and mild mitral regurgitation [Figure 1]. The isolate was identified as E. coli and the sensitivity results depicted ESBL producer susceptible to carbapenems only. Antibiotics were switched to imipenem-cilastin that improved her clinical condition. Patient was transferred to nursing home with intravenous antibiotic therapy for six weeks. Surgical treatment was not considered because of clinical response to the antibiotic therapy, mild regurgitation of mitral valve and high risk for surgery because of co-morbidities.
Figure 1

Transesophageal echocardiogram – bioprosthetic mitral valve area showing 5 mm size, mobile, echogenic structure attached to the peripheral rim

Transesophageal echocardiogram – bioprosthetic mitral valve area showing 5 mm size, mobile, echogenic structure attached to the peripheral rim E. coli is a common organism to cause bacteremia in hospitalized patients, but the endocarditis due to E. coli is rare. The epidemiology and microbiological etiology of PVE have changed and there is a marked increase in PVE caused by Enterococcus.[2] The major risk factors for infections with ESBL-producing organisms are advanced age, female sex, diabetes mellitus, underlying urinary tract infection, prolonged hospital stay, duration of ICU stay and prior exposures to cephalosporins, quinolones and three or more courses of antibiotic therapy within the preceding year.[3] E. coli endocarditis is associated with higher rate of intracardiac abscess, sepsis and in-hospital mortality.[4] Modified Duke's criteria have lower sensitivity in diagnosis of PVE.[1] Blood culture is the best identification method providing live bacteria for susceptibility testing. TEE has higher sensitivity and specificity in detecting vegetations, valve abscesses, fistulae, perivalvular regurgitation and prosthetic valve dehiscence. The carbapenems are commonly used as the drug of choice for severe infections due to ESBL-producing Enterobacteriaceae. The presence of ESBL confers resistance to third and fourth-generation cephalosporins and monobactams and co-resistance to fluoroquinolones, tetracyclines, and aminoglycosides.[5] Surgical treatment for PVE is associated with high mortality but the prognosis is better with the early surgery, radical debridement of infected tissue and in presence of complications like heart failure and valve abscesses.[6]
  6 in total

Review 1.  The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter.

Authors:  David M Livermore; Neil Woodford
Journal:  Trends Microbiol       Date:  2006-07-31       Impact factor: 17.079

Review 2.  Indications for surgery and operative techniques in infective endocarditis in the present day.

Authors:  María Angeles Gutierrez-Martin; Juan Galvez-Aceval; Omar A Araji
Journal:  Infect Disord Drug Targets       Date:  2010-02

Review 3.  Escherichia coli endocarditis: seven new cases in adults and review of the literature.

Authors:  S Branger; J P Casalta; G Habib; F Collard; D Raoult
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-08       Impact factor: 3.267

4.  A 10-year survey of clinically significant blood culture isolates and antibiotic susceptibilities from adult patients with hematological diseases at a major Swedish hospital.

Authors:  H Fredlund; M Björeman; J Kjellander; L Sjöberg; L Bjorne; A L Ohlin
Journal:  Scand J Infect Dis       Date:  1990

5.  Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

6.  Non-HACEK gram-negative bacillus endocarditis.

Authors:  Susan Morpeth; David Murdoch; Christopher H Cabell; Adolf W Karchmer; Paul Pappas; Donald Levine; Francisco Nacinovich; Pierre Tattevin; Núria Fernández-Hidalgo; Stuart Dickerman; Emilio Bouza; Ana del Río; Tatjana Lejko-Zupanc; Auristela de Oliveira Ramos; Diana Iarussi; John Klein; Catherine Chirouze; Roger Bedimo; G Ralph Corey; Vance G Fowler
Journal:  Ann Intern Med       Date:  2007-12-18       Impact factor: 25.391

  6 in total
  4 in total

1.  Infective Endocarditis Caused by Extended-Spectrum Beta-Lactamase-Producing Escherichia coli: A Case Report.

Authors:  Tsuneaki Kenzaka; Yuto Shinkura; Shizuo Kayama; Liansheng Yu; Sayoko Kawakami; Motoyuki Sugai; Satoru Kawasaki
Journal:  Infect Drug Resist       Date:  2021-08-25       Impact factor: 4.003

2.  Emphysematous endocarditis caused by AmpC beta-lactamase-producing Escherichia coli: A case report.

Authors:  Chung-Jong Kim; Jeong-Eun Yi; Yookyung Kim; Hee Jung Choi
Journal:  Medicine (Baltimore)       Date:  2018-02       Impact factor: 1.889

Review 3.  Native valve endocarditis due to Escherichia coli infection: a case report and review of the literature.

Authors:  Nobuhiro Akuzawa; Masahiko Kurabayashi
Journal:  BMC Cardiovasc Disord       Date:  2018-10-19       Impact factor: 2.298

4.  Extended spectrum beta lactamase producing Escherichia coli tricuspid valve endocarditis.

Authors:  Rami Waked; Gebrael Saliba; Nabil Chehata; Elie Haddad; Marie Chedid; Jacques Choucair
Journal:  IDCases       Date:  2020-02-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.